JPS62185026A - Remedy for itching dermatopathy - Google Patents
Remedy for itching dermatopathyInfo
- Publication number
- JPS62185026A JPS62185026A JP61025487A JP2548786A JPS62185026A JP S62185026 A JPS62185026 A JP S62185026A JP 61025487 A JP61025487 A JP 61025487A JP 2548786 A JP2548786 A JP 2548786A JP S62185026 A JPS62185026 A JP S62185026A
- Authority
- JP
- Japan
- Prior art keywords
- decoctions
- cordata
- plants
- kudo
- dermatopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003251 Pruritus Diseases 0.000 title abstract description 5
- 230000007803 itching Effects 0.000 title abstract description 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 10
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 10
- 241001330002 Bambuseae Species 0.000 claims description 10
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 10
- 239000011425 bamboo Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 5
- 230000001823 pruritic effect Effects 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 12
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 4
- 206010039986 Senile pruritus Diseases 0.000 abstract description 4
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 206010020649 Hyperkeratosis Diseases 0.000 abstract description 3
- 208000001126 Keratosis Diseases 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 abstract description 3
- 238000009835 boiling Methods 0.000 abstract description 2
- 241001365032 Isodon trichocarpus Species 0.000 abstract 3
- 206010012442 Dermatitis contact Diseases 0.000 abstract 2
- 240000007849 Macleaya cordata Species 0.000 abstract 2
- 208000010247 contact dermatitis Diseases 0.000 abstract 2
- 206010009869 cold urticaria Diseases 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000002674 ointment Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000111332 Molanna albicans Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分IP1
本発明は掻痒性皮膚疾患例えば老人性掻痒症、寒冷性辱
麻疹、角化症、乾皮症、アトピー性皮膚炎等の外用治療
剤組成物に関する。[Detailed Description of the Invention] [Industrial Application IP1] The present invention provides a composition for external treatment of pruritic skin diseases such as senile pruritus, cold measles, keratosis, xeroderma, and atopic dermatitis. relating to things.
[従来の技術]
掻痒性皮膚疾患は近時複雑化した社会生活に心理的に十
分に馴染まない等、的確な究明結果が得られていない未
詳の原因によって、多くのひと殊に腺病質的な若年者と
か逐次増加している高齢者とかにかなり普遍的に見られ
る疾患であるが、糖尿病、肝障害、痛風、腎障害、内分
泌障害、外的要因によろカブレ、II!瘍、消化系障害
、ビタミン欠乏、ホルモン不均衡、老化、代謝異常、カ
ルシウム不足等に関連する程度に言われ、その機構も不
明且つ効果的な治療法もないのが現状である。[Prior art] Pruritic skin diseases affect many people, especially young people with pathological conditions, due to unknown causes for which accurate investigation results have not been obtained, such as the inability to psychologically adapt to the social life that has become more complicated in recent years. It is a disease that is fairly universally seen in elderly people and is increasing in number, but it is caused by diabetes, liver damage, gout, kidney damage, endocrine disorders, and rash due to external factors. It is said to be associated with cancer, digestive system disorders, vitamin deficiencies, hormonal imbalances, aging, metabolic abnormalities, calcium deficiency, etc., and at present the mechanism is unknown and there is no effective treatment.
殆ど経験的にビタミンA−D軟膏、ビタミンE軟膏、副
腎皮質ホルモン剤軟膏等の塗布、抗ヒスタミン剤の内服
又は同軟膏の外用、上記関連疾病の治療等が行われてい
るのであるが、勿論決定的な治療剤はまだ得られていな
い。Most empirically, the application of vitamin A-D ointment, vitamin E ointment, adrenal corticosteroid ointment, etc., oral administration of antihistamines or external use of the same ointment, treatment of the above-mentioned related diseases, etc. have been used, but of course there is no definitive cure. No therapeutic agent has yet been obtained.
[問題点を解消するための手段]
本発明者らは種々生理活性ある天然物由来のものの効果
を研究して来た処、タケニグサ及びクロバナヒキオコシ
の煎液が例えば老人性掻痒症、寒冷性尊麻疹、角化症、
乾皮症、カブレ、アトピー性皮膚炎等の掻痒性皮膚疾患
の治療に極めて有効であることを見出し、本発明を完成
した。[Means for Solving the Problems] The present inventors have been researching the effects of various physiologically active natural products, and found that a decoction of bamboo rush and black-and-white broom has been found to be effective against senile pruritus and cold measles, for example. , keratosis,
The present invention was completed based on the discovery that the present invention is extremely effective in treating pruritic skin diseases such as xeroderma, rash, and atopic dermatitis.
本発明治療剤はタケニグサ及びクロバナヒキオコシの!
?j(出液から成るが、夫々単独のり!(液では有効で
な(、特にタケニグサ単独の煎液では場合によっては寧
ろ逆にカブレを来たするともあり得るのに、本発明治療
剤すj(液から成る組成物に於いてはじめて著効を示す
ことは、予測を絶するものであった。The therapeutic agent of the present invention is derived from Bamboo rush and Bamboo shoots!
? (Although it consists of exudate, it is not effective when used as a liquid alone. (In particular, a decoction of bamboo rush alone may even cause rashes depending on the case.) However, the therapeutic agent of the present invention (It was completely unexpected that a composition consisting of a liquid would show remarkable effects for the first time.
本発明組成物にはその皮膚浸透性を高めるために、適量
のアルコールとかグリセリンとかを添加するのが通常で
あるが、防菌防腐の効果を併せ期待するには、一般にア
ルコールの添加が便利である。またカルボキシメチルセ
ルローズ等のセルローズ誘導体、カルボキシビニルポリ
マー等の合成重合体、アルギン酸等の天然物、その他適
宜の増粘剤を利用するなどして、クリーム状とか砿膏状
とかにするなども差支えないこと勿論である。It is usual to add an appropriate amount of alcohol or glycerin to the composition of the present invention in order to increase its skin permeability, but it is generally convenient to add alcohol in order to obtain antibacterial and antiseptic effects. be. It is also possible to use cellulose derivatives such as carboxymethyl cellulose, synthetic polymers such as carboxyvinyl polymers, natural products such as alginic acid, and other appropriate thickeners to create cream-like or plaster-like forms. Of course.
タケニグサは学名Maeleaya eordata
、向陽地に自生する大型の多年草であり、古来その全草
を乾燥したものは消炎、消腫、解毒、殺虫の作用が見ら
れ、悪痕、膜種、潰瘍、中耳炎等に用いられる外用民間
薬であった。クロパナヒキオコシは学名Rabdosi
a trichoearpa 、山野に自生する宿根多
年生植物であって延命草とも呼ばれ、健冑薬とすると知
られているが、近年トリコラブダールと総称される一群
の化学成分が確認され、これに抗腫瘍効果が見出されて
いる。なおこれら両植物の前液から成る組成物が白癖菌
に起因する皮膚疾患の治癒剤としても著効があり、本発
明者らはその用途について特願昭60−第231787
号の発明を完成している。The scientific name of bamboo rush is Maeleya eordata
, is a large perennial plant that grows naturally in the Koyo area, and since ancient times, the dried whole plant has been shown to have anti-inflammatory, anti-tumor, detoxifying, and insecticidal effects, and has been used externally to treat bad marks, membranes, ulcers, otitis media, etc. It was medicine. The scientific name of Rabdosi is Rabdosi.
A trichoearpa is a perennial perennial plant that grows naturally in the mountains and fields. It is also called Enmeiso, and is known to be a health medicine. Recently, however, a group of chemical components collectively known as trichorhabdal have been identified, and this has been shown to have antitumor properties. It has been found to be effective. Furthermore, a composition consisting of the pre-liquids of these two plants is also highly effective as a curative agent for skin diseases caused by M. albicans, and the present inventors have proposed its use in Japanese Patent Application No. 231787-1983.
He has completed the invention of No.
本発明の目的のためには両植物の伺れの部分を用いても
よいが、経済的には全草を即ち棄てる処なく用いるのが
好ましい。両植物は野性しているが栽培も容易で、残さ
れた根から植物体を再生してもよく餅種によって殖やす
ことも容易である。For the purposes of the present invention, the thin parts of both plants may be used, but economically it is preferable to use the whole plant, that is, without any waste. Although both plants are wild, they are easy to cultivate, and the plants can be regenerated from the remaining roots, and propagated using mochi seeds.
全草を使うといっても根を残して翌年に備えることは賢
明である。Even if you use the whole plant, it is wise to leave the roots for next year.
採取した植物体については通常の通り異物を除去し、通
例取り扱い易い程度に乾燥切断する。先ずタケニブ91
重量を水4重量程度の中に投入煮沸する。その時間は普
通30分〜1時間で十分であるが、更に延長しても支障
はない。煮沸終期に使用タケニグサと略々同重量のクロ
バナヒキオコシを投入する。熱源を去り充分にできれば
アトマイザ−とかジューサーとかで混合撹拌しながら放
冷する。略々室温に迄冷えた処で濾過する。濾液に例え
ばその10%容量のアルコールを添加するが、アルコー
ルの添加は必須ではない。斯くして本発明治療剤組成物
が得られる。Foreign matter is removed from the collected plants as usual, and the plants are dried and cut to the extent that they are easy to handle. First, Takenib 91
Pour the weight into about 4 weight of water and boil. Generally, 30 minutes to 1 hour is sufficient, but there is no problem in extending the time further. At the end of boiling, approximately the same weight of the bamboo rush used as the bamboo rush is added. Remove the heat source and, if possible, leave to cool while stirring with an atomizer or juicer. Cool to approximately room temperature and filter. For example, 10% of its volume of alcohol is added to the filtrate, although the addition of alcohol is not essential. In this way, the therapeutic composition of the present invention is obtained.
[発明の効果] 本発明治療剤は、掻痒患部に一日数回塗布すればよい。[Effect of the invention] The therapeutic agent of the present invention may be applied to the itchy area several times a day.
従来如何なる薬剤等によっても治療の目的を達しなかっ
た症状にも、夫々有効な結果を招来し、斯界に貢献する
処極めて大である。The present invention will bring about effective results in treating symptoms for which conventional drugs have not been able to achieve the goal of treatment, and will greatly contribute to this field.
〔実施例]
以下に実施例及び試験例を示すが、本発明はこれらの例
に限定されるものではない。[Example] Examples and test examples are shown below, but the present invention is not limited to these examples.
実施例1、
数日陰干しにし、小片に切断した植物体を使用した。タ
ケニグサ100gを水400gに投入、加熱して30分
間煮沸する。クロバナヒキオコシ100gを投入すると
同時に熱源を去り、熱時にこの水性混合物をミキサーに
移して、強く攪拌する。室温近くに冷えた処で化学実験
用の大型濾紙を用いて濾過する。暗赤褐色の濁りのない
濾液が得られる。Example 1 A plant body dried in the shade for several days and cut into small pieces was used. Add 100g of bamboo rush to 400g of water, heat and boil for 30 minutes. At the same time as 100 g of Black Banana Cucumber was added, the heat source was removed, and when the mixture was hot, the aqueous mixture was transferred to a mixer and stirred vigorously. Filter in a place that has cooled to near room temperature using a large filter paper for chemical experiments. A dark reddish-brown clear filtrate is obtained.
実施例2、
実施例1の濾液100m1を採り、これにアルコール1
0o+lt−混和する。暗赤褐色の濁りのない芳香ある
溶液が得られる。Example 2: Take 100 ml of the filtrate from Example 1 and add 1 ml of alcohol to it.
0o+lt- mix. A dark reddish-brown, clear and aromatic solution is obtained.
実施例3、
実施例1の濾液100m1に架橋型ポリアクリル酸(市
販品名:八イピスワコ−104;和光純薬工業株式会社
製)の粉末o、5gを混和し、撹拌を続けながらトリエ
タノールアミン数滴を与えて中和する。暗赤褐色で濁り
のないチクソト實ピックなりリームが得られる。実施例
2の溶液を用いても同様である。Example 3: 5 g of powder of cross-linked polyacrylic acid (commercial product name: Yaipiswako-104; manufactured by Wako Pure Chemical Industries, Ltd.) was mixed with 100 ml of the filtrate of Example 1, and while stirring, the number of triethanolamines was increased. Give drops to neutralize. You can get a dark reddish-brown color with no turbidity. The same holds true when the solution of Example 2 is used.
試験例11
抗ヒスタミン軟膏、副資皮質ホルモン剤款膏、ビタミン
A−D軟膏、ビタミンE軟膏等既存の外用薬を単独又は
併用して長期に使用しながら、改善の兆の全くなかった
患者を選び、夫々本発明治療剤組成物のみの塗布を行わ
せた。σ口始2日目〜3日目には治療の効果が現われて
その掻痒は消失し、3日目〜5日目に発疹は大部分消失
し、1〜2週間後には角化部に新鮮な皮膚を認めるに至
った。この間疼痛等の副作用的なことは、絶無であった
。状況を次表に略記する。Test Example 11 A patient who showed no signs of improvement while using existing external medicines such as antihistamine ointment, corticosteroid ointment, vitamin A-D ointment, vitamin E ointment, etc. alone or in combination for a long period of time. The therapeutic agent composition of the present invention alone was applied to each of the selected mice. The effect of the treatment appears and the itching disappears on the 2nd to 3rd day, the rash mostly disappears on the 3rd to 5th day, and after 1 to 2 weeks, a fresh rash appears on the keratinized area. I have come to recognize that my skin has a unique appearance. During this time, there were no side effects such as pain. The situation is summarized in the table below.
特許出願人 株式会社 仁天堂薬局 特許出願人 佐 藤 洪 基 手続補正書 昭和62年q月6日Patent applicant: Nitendo Pharmacy Co., Ltd. Patent applicant: Hong Moto Sato Procedural amendment June 6th, 1986
Claims (1)
性皮膚疾患治療剤。A therapeutic agent for pruritic skin diseases consisting of a decoction of bamboo rush and black-and-white bamboo shoots.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61025487A JPS62185026A (en) | 1986-02-07 | 1986-02-07 | Remedy for itching dermatopathy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61025487A JPS62185026A (en) | 1986-02-07 | 1986-02-07 | Remedy for itching dermatopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62185026A true JPS62185026A (en) | 1987-08-13 |
Family
ID=12167409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61025487A Pending JPS62185026A (en) | 1986-02-07 | 1986-02-07 | Remedy for itching dermatopathy |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62185026A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0987189A (en) * | 1995-09-19 | 1997-03-31 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne |
JP2006176436A (en) * | 2004-12-22 | 2006-07-06 | Kao Corp | Scf expression inhibitor |
JP2011088854A (en) * | 2009-10-22 | 2011-05-06 | Kao Corp | Involucrin expression inhibitor |
CN106943557A (en) * | 2017-03-24 | 2017-07-14 | 成都海青生物科技有限公司 | It is a kind of effectively to treat pill medicine of nettle rash and preparation method thereof |
-
1986
- 1986-02-07 JP JP61025487A patent/JPS62185026A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0987189A (en) * | 1995-09-19 | 1997-03-31 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne |
JP2006176436A (en) * | 2004-12-22 | 2006-07-06 | Kao Corp | Scf expression inhibitor |
JP4647991B2 (en) * | 2004-12-22 | 2011-03-09 | 花王株式会社 | SCF expression inhibitor |
JP2011088854A (en) * | 2009-10-22 | 2011-05-06 | Kao Corp | Involucrin expression inhibitor |
CN106943557A (en) * | 2017-03-24 | 2017-07-14 | 成都海青生物科技有限公司 | It is a kind of effectively to treat pill medicine of nettle rash and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6530817B2 (en) | Acne removal skin care product and method of manufacturing the same | |
DE69919287T2 (en) | Ethyl acetate extract of indigo plant | |
DK2155222T3 (en) | Extract of Trigonella foenum-graecum | |
WO2008140200A1 (en) | External compositions for the skin | |
CN102579305B (en) | Natural medicine toothpaste with saussurea involucrata as major material | |
CN108272862B (en) | Pudilan oral spray and preparation method thereof | |
CN103520502A (en) | Chinese medicinal preparation for treating gingivitis and preparation method thereof | |
CN107349171B (en) | A kind of effectively antibacterial, sterilization and the mouthwash for accelerating canker sore healing | |
ES2856498T3 (en) | Daphne laureola extract and its use for the treatment of skin diseases | |
CN108685987A (en) | A kind of Chinese medicine composition and its preparation method and application | |
JPS62185026A (en) | Remedy for itching dermatopathy | |
CN106581303A (en) | Mouth wash for preventing recurrent canker sore | |
CN106963912B (en) | Dalbergia wood compound composition for treating eczema and preparation method thereof | |
Roqaiya et al. | A review on medicinal aspect of alum in Unani medicine and scientific studies | |
JPH03163026A (en) | Vasodilator | |
CN102836277B (en) | Medicine composition for treating periodontal diseases as well as preparation method and application thereof | |
CN112353846A (en) | A nail polish remover and its preparation method | |
CN112755132A (en) | Traditional Chinese medicine disinfection composition and preparation method thereof | |
CN104258092A (en) | Gargle for treating recurrent aphthous ulcer and periodontitis and preparation method thereof | |
KR20140114921A (en) | Aloe composition for moisturizing the skin | |
CN102357145A (en) | Externally applied ointment for treating baldness | |
CN102805785B (en) | Tai chi oil and preparation method thereof | |
JPS63310836A (en) | Antitrichophytic remedy | |
CN105343266A (en) | Psoriasis treating ointment | |
TWI524889B (en) | A method of manufacturing an herbal extract for wound healing and the herbal extract thereof |